Acoustic Coordinated Reset (CR®) Neuromodulation for the Treatment of Chronic Tonal Tinnitus ("RESET Real Life")

NCT ID: NCT01435317

Last Updated: 2014-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Confirmation of efficacy and safety of acoustic CR®-neuromodulation for the treatment of chronic tinnitus patients using the CE marked ANM T30 CR®-system in a real life outpatient setting.

* Identification of early indicators for therapy success
* Comparison of different patient groups regarding: tinnitus severity, tinnitus duration, level of hearing loss, stimulation patterns, unilateral monotonal vs. all other complex forms
* Representative set of safety data in a broad patient spectrum
* Measurement of tinnitus burden (TBF-12 Questionnaire)
* Generation of longterm compliance data

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tinnitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard

Standard treatment with the ANM T30 CR®-System

Group Type EXPERIMENTAL

ANM T30 CR®-System

Intervention Type DEVICE

Stimulation for 4-6h/day for a time of 1 year

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ANM T30 CR®-System

Stimulation for 4-6h/day for a time of 1 year

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic subjective tonal chronical (\> 3 months) tinnitus
* \<60dB hearing loss
* men and women ≥18 years old

Exclusion Criteria

* serious neurologic
* psychiatric or internistic disease
* objective tinnitus
* Morbus Menière
* craniomandibular triggered tinnitus
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CERES GmbH

INDUSTRY

Sponsor Role collaborator

ANM Adaptive Neuromodulation GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Uwe Brinkmann, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

HNO-Gemeinschaftspraxis Hamm-Ahlen-Oelde

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. med. Mueller

Augsburg, , Germany

Site Status

Dr. med. Jan Loehler

Bad Bramstedt, , Germany

Site Status

Praxisverbund Berlin

Berlin, , Germany

Site Status

Dr. med. Daniel Osterland

Berlin, , Germany

Site Status

Dres. med. Bodlien/Lingner/Kassuhn

Braunschweig, , Germany

Site Status

Praxis HNO Koeln Nord

Cologne, , Germany

Site Status

Dres. Lindenberger Wilhelm Ecke Elies Sperl Brackmann

Frankfurt, , Germany

Site Status

Dr. med. Fleissner

Freiburg im Breisgau, , Germany

Site Status

EuromedClinic

Fürth, , Germany

Site Status

Dr. med. Hegemann-Gaertner

Grevenbroich, , Germany

Site Status

Dipl.-Med. Kathrin Stoelzer

Halle, , Germany

Site Status

Dr. med. Hahbrock

Koblenz, , Germany

Site Status

Dr. med. Wichmann

Krefeld, , Germany

Site Status

Roemerwallklini Gmbh

Mainz, , Germany

Site Status

HNO-Gemeinschaftspraxis im Zentrum

Mannheim, , Germany

Site Status

Dr .med. Tatjana von Stackelberg

Meerbusch, , Germany

Site Status

Dr. med. Ullmann

Melsungen, , Germany

Site Status

Dr. med. Wurzer

München, , Germany

Site Status

Dres. med. Bergmann und Davies

Nürtingen, , Germany

Site Status

Dr. med Uwe Brinkmann

Oelde, , Germany

Site Status

Dr. med. Huegelschaeffer

Philippsburg, , Germany

Site Status

Dr. med. Axel Roesler

Radevormwald, , Germany

Site Status

Dres. med. Ramming und Waller

Schweinfurt, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCT2011-08-26

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ICCAC-ToNF & Tinnitus
NCT03895047 COMPLETED NA